Many companies in regulated industries such as pharmaceuticals are pouring money into AI. But a lot of that work ultimately doesn’t see the light of day, due to the compliance, validation, and audit requirements that govern every system they deploy.
Iridius, a Seattle startup founded by two Microsoft veterans working with alumni from companies such as Amazon and OpenAI, has raised $8.6 million in seed funding to go after this problem, with Accenture as both an investor and strategic partner.
The startup’s pitch: Its technology translates regulatory requirements and company policies into code so that compliance is enforced automatically as AI systems run, not just documented after the fact. Actions by agents, meanwhile, are automatically logged for audit.
The company’s initial focus is life sciences, including pharmaceutical companies, but it sees broader applications across regulated industries over time.
Chalfen Ventures led the seed round, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. The consulting giant is also working with Iridius and prospective pharmaceutical customers to identify where compliance automation can deliver the biggest returns in the drug development life cycle.
How they got to pharma: Iridius CEO and co-founder Mike Kropp, who spent 21 years in engineering and product leadership roles at Microsoft before working at Amazon Web Services, said the startup’s founding team initially pitched some of their former Microsoft colleagues on the broader idea of compliance infrastructure for enterprise AI.
The initial response: no one cared about AI compliance.
But by July of last year, that had changed. Microsoft began introducing the startup to some of the tech giant’s largest pharmaceutical customers, whose AI pilots were getting all the way to the edge of production before compliance tripped them up.
“The degree of specificity and scope in the pharma space as it relates to compliance is massive,” Kropp said. He cited prospective customers that spend $1.5 billion a year on compliance, and need to maintain 70,000 internal standard operating procedures that must be reconciled against external regulations.
Deep roster: Kropp started Iridius in 2024 with co-founder Alistair Lowe-Norris, a 23-year Microsoft veteran who previously served as chief change officer under Microsoft CEO Satya Nadella and is now Iridius’s chief product and responsible AI officer.
Other company leaders include:
- Mark Turley, co-founder, CFO and COO, who previously led accounting and financial operations at Highspot.
- Peter Larsen, the company’s chief technology officer, who joined from AWS, where he was a senior manager of solution architecture.
- Spencer Bentley, the company’s AI technical fellow, who is based in the U.K. and has worked as an OpenAI contractor since 2021, running its developer forum.
- Laura McFadden, VP of go-to-market and strategy, who previously held finance roles at Amazon spanning healthcare and consumer devices.
Clark Golestani, the former CIO and president of emerging businesses at Merck, joined the Iridius board last October after meeting Kropp at an industry event.
The company has also built a deep bench of advisors: George Llado, former CIO at Alexion; Sean Lennon, former CIO at Medtronic; Jeff Keisling, former CIO at Pfizer; Jeff Brittain, former CIO at Bayer; Uli Homann, a corporate vice president and distinguished architect at Microsoft; and Hal Stern, former CIO at Johnson & Johnson R&D.
Iridius has 11 employees, the majority in the Seattle area.
How it works: The Iridius platform has two main components:
- A knowledge engine breaks regulations down, rule-by-rule, and stores them in a database AI agents can query in real time.
- A solution factory uses those rules to help customers design, build, and connect AI workflows to existing enterprise systems.
Landscape: Iridius is entering a growing field. A wave of AI governance tools has emerged to monitor model behavior in enterprise environments, and other startups have begun applying AI agents to compliance work in supply chain, finance, and life sciences.
Kropp said the company is taking a different approach by embedding compliance into the execution of AI workflows rather than monitoring them from the outside.
It’s also treating existing tech platforms, such as Veeva Systems, the dominant software vendor in life sciences, as integration possibilities rather than competitors.
What’s next: Iridius has not yet launched its product commercially, but has signed a co-development agreement with one pharmaceutical customer, and is in discussions with others. The funding will go in part to hiring, including expanding its AI engineering team.
Read the full article here
